{
    "ticker": "JUNT",
    "name": "Juno Therapeutics, Inc.",
    "description": "Juno Therapeutics, Inc. is a biotechnology company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded in 2013 by a team of leading scientists and entrepreneurs, Juno is committed to harnessing the power of the immune system to fight cancer. The company has pioneered the development of chimeric antigen receptor (CAR) T cell therapies, which modify a patient's own T cells to better recognize and attack cancer cells. Juno's lead products include JCAR017, an investigational therapy for patients with relapsed or refractory B cell malignancies, and several other promising candidates in various stages of clinical trials. Juno collaborates with numerous academic institutions and industry partners to advance its research and expand its pipeline of therapies. With a mission to provide transformative therapies to patients, Juno Therapeutics continues to push the boundaries of cancer treatment, aiming to deliver hope and improved outcomes for those affected by this devastating disease.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "2013",
    "website": "https://www.junotherapeutics.com",
    "ceo": "Jennifer Dyer",
    "social_media": {
        "twitter": "https://twitter.com/junotherapeutics",
        "linkedin": "https://www.linkedin.com/company/junotherapeutics"
    },
    "investor_relations": "https://investors.junotherapeutics.com",
    "key_executives": [
        {
            "name": "Jennifer Dyer",
            "position": "CEO"
        },
        {
            "name": "Robert A. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapies",
            "products": [
                "JCAR017",
                "JCAR014"
            ]
        }
    ],
    "seo": {
        "meta_title": "Juno Therapeutics, Inc. | Innovative Cellular Immunotherapies",
        "meta_description": "Explore Juno Therapeutics, Inc., a leader in biotechnology developing CAR T cell therapies for cancer treatment. Learn about their innovative products and commitment to patient care.",
        "keywords": [
            "Juno Therapeutics",
            "CAR T Cell Therapy",
            "Cancer Treatment",
            "Biotechnology",
            "Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What does Juno Therapeutics focus on?",
            "answer": "Juno Therapeutics focuses on developing cellular immunotherapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Juno Therapeutics?",
            "answer": "Jennifer Dyer is the CEO of Juno Therapeutics, Inc."
        },
        {
            "question": "Where is Juno Therapeutics headquartered?",
            "answer": "Juno Therapeutics is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What are Juno's main products?",
            "answer": "Juno's main products include JCAR017 and JCAR014, which are investigational therapies for cancer."
        },
        {
            "question": "When was Juno Therapeutics founded?",
            "answer": "Juno Therapeutics was founded in 2013."
        }
    ],
    "competitors": [
        "CARA",
        "EDIT",
        "CRSP",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "ABBV"
    ]
}